Citigroup’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-928
| Closed | -$16K | – | 7849 |
|
|
2020
Q4 | $16K | Buy |
928
+73
| +9% | +$1.02K | ﹤0.01% | 6781 |
|
|
2020
Q3 | $10K | Sell |
855
-421
| -33% | -$5.59K | ﹤0.01% | 6663 |
|
|
2020
Q2 | $17K | Sell |
1,276
-311
| -20% | -$3.74K | ﹤0.01% | 6758 |
|
|
2020
Q1 | $15K | Buy |
1,587
+332
| +26% | +$4.64K | ﹤0.01% | 6871 |
|
|
2019
Q4 | $21K | Sell |
1,255
-1,607
| -56% | -$26.1K | ﹤0.01% | 6924 |
|
|
2019
Q3 | $48K | Sell |
2,862
-15,083
| -84% | -$209K | ﹤0.01% | 6161 |
|
|
2019
Q2 | $247K | Buy |
17,945
+10,924
| +156% | +$167K | ﹤0.01% | 5088 |
|
|
2019
Q1 | $121K | Buy |
7,021
+678
| +11% | +$10.7K | ﹤0.01% | 5569 |
|
|
2018
Q4 | $81K | Sell |
6,343
-626
| -9% | -$9.49K | ﹤0.01% | 5841 |
|
|
2018
Q3 | $113K | Buy |
6,969
+3,324
| +91% | +$47.5K | ﹤0.01% | 5783 |
|
|
2018
Q2 | $47K | Buy |
3,645
+457
| +14% | +$6.17K | ﹤0.01% | 6345 |
|
|
2018
Q1 | $40K | Buy |
3,188
+627
| +24% | +$7.63K | ﹤0.01% | 6343 |
|
|
2017
Q4 | $36K | Buy |
2,561
+2,491
| +3,559% | +$36.5K | ﹤0.01% | 6401 |
|
|
2017
Q3 | $1K | Sell |
70
-172
| -71% | -$2.8K | ﹤0.01% | 7193 |
|
|
2017
Q2 | $4K | Buy |
242
+216
| +831% | +$3.23K | ﹤0.01% | 6838 |
|
|
2017
Q1 | $0 | Sell |
26
-33,437
| -100% | -$478K | ﹤0.01% | 7410 |
|
|
2016
Q4 | $500K | Buy |
33,463
+31,641
| +1,737% | +$444K | ﹤0.01% | 4380 |
|
|
2016
Q3 | $23K | Buy |
1,822
+527
| +41% | +$5.29K | ﹤0.01% | 6138 |
|
|
2016
Q2 | $12K | Sell |
1,295
-12,771
| -91% | -$125K | ﹤0.01% | 6471 |
|
|
2016
Q1 | $139K | Buy |
14,066
+11,353
| +418% | +$116K | ﹤0.01% | 5422 |
|
|
2015
Q4 | $31K | Buy |
2,713
+2,639
| +3,566% | +$32.7K | ﹤0.01% | 6251 |
|
|
2015
Q3 | $1K | Sell |
74
-8,771
| -99% | -$119K | ﹤0.01% | 7261 |
|
|
2015
Q2 | $123K | Sell |
8,845
-31,365
| -78% | -$424K | ﹤0.01% | 4835 |
|
|
2015
Q1 | $566K | Buy |
40,210
+37,978
| +1,702% | +$517K | ﹤0.01% | 3622 |
|
|
2014
Q4 | $30K | Buy |
2,232
+1,779
| +393% | +$24.3K | ﹤0.01% | 6011 |
|
|
2014
Q3 | $7K | Buy |
453
+343
| +312% | +$5.25K | ﹤0.01% | 6437 |
|
|
2014
Q2 | $2K | Sell |
110
-841
| -88% | -$15.1K | ﹤0.01% | 6807 |
|
|
2014
Q1 | $19K | Sell |
951
-2,068
| -68% | -$44.7K | ﹤0.01% | 6066 |
|
|
2013
Q4 | $59K | Buy |
+3,019
| New | +$53.4K | ﹤0.01% | 5629 |
|
Citigroup's OXFD Position: Q1 2021 in Review
Citigroup sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q1 2021, closing a stake of 928 shares — an estimated $16K sold.
Citigroup first reported a position in OXFD in Q4 2013 and held it in 29 quarters. The position peaked at $566K in Q1 2015. 0 funds tracked by Wall St. Rank hold OXFD as of Q1 2021.
- Citigroup reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q1 2021 after selling out during the quarter.
- Citigroup sold 928 Oxford Immunotec Global PLC Ordinary Shares shares in Q1 2021, an estimated $16K.
- Citigroup first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q4 2013 and held it in 29 quarters.
- Citigroup's Oxford Immunotec Global PLC Ordinary Shares position peaked at $566K in Q1 2015.
- 0 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q1 2021.
Based on Citigroup's 13F filing for Q1 2021, filed 13 May 2021.